Interleukin-3-induced activation of the JAK/STAT pathway is prolonged by proteasome inhibitors

Blood

Volumn 91, Issue 9, 1998, Pages 3182-3192

  Callus, Bernard A ^a   Mathey Prevot, Bernard ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 3; MITOGEN ACTIVATED PROTEIN KINASE; PROTEASOME; PROTEIN KINASE; STAUROSPORINE; VANADIC ACID;

ANIMAL CELL; ARTICLE; IMMUNOREGULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEINASE INHIBITION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

EID: 0032080245     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.9.3182     Document Type: Article

References (59)

1. Coux O, Tanaka K, Goldberg AL: Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem 65:801, 1996
2. Hochstrasser M: Ubiquitin-dependent protein degradation. Annu Rev Genet 30:405, 1996
3. King RW, Peters JM, Tugendreich S, Rolfe M, Hieter P, Kirschner MW: A 20S complex containing CDC27 and CDC16 catalyzes the mitosis-specific conjugation of ubiquitin to cyclin B. Cell 81:279, 1995
4. Seufert W, Futcher B, Jentsch S: Role of a ubiquitin-conjugating enzyme in degradation of S- and M-phase cyclins. Nature 373:78, 1995
5. Amon A, Irniger S, Nasmyth K: Closing the cell cycle circle in yeast: G2 cyclin proteolysis initiated at mitosis persists until the activation of G1 cyclins in the next cycle. Cell 77:1037, 1994
6. Deshaies RJ, Chau V, Kirschner M: Ubiquitination of the G1 cyclin Cln2p by a Cdc34p-dependent pathway. EMBO J 14:303, 1995
7. Yaglom J, Linskens MH, Sadis S, Rubin DM, Futcher B, Finley D: p34Cdc28-mediated control of Cln3 cyclin degradation. Mol Cell Biol 15:731, 1995
8. Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, Hwang D, Goldberg AL: Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78:761, 1994
9. Treier M, Staszewski LM, Bohmann D: Ubiquitin-dependent c-Jun degradation in vivo is mediated by the delta domain. Cell 78:787, 1994
10. Miyamoto S, Maki M, Schmitt MJ, Hatanaka M, Verma IM: Tumor necrosis factor alpha-induced phosphorylation of I kappa B alpha is a signal for its degradation but not dissociation from NF-kappa B. Proc Natl Acad Sci USA 91:12740, 1994
11. Brown K, Gerstberger S, Carlson L, Franzoso G, Siebenlist U: Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation. Science 267:1485, 1995
12. Traenckner EB, Pahl HL, Henkel T, Schmidt KN, Wilk S, Baeuerle PA: Phosphorylation of human I kappa B-alpha on serines 32 and 36 controls I kappa B-alpha proteolysis and NF-kappa B activation in response to diverse stimuli. EMBO J 14:2876, 1995
13. Chen Z, Hagler J, Palombella VJ, Melandri F, Scherer D, Ballard D, Maniatis T: Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway. Genes Dev 9:1586, 1995
14. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T: The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 78:773, 1994
15. Hicke L, Reizman H: Ubiquitination of a yeast plasma membrane receptor signals its ligand-stimulated endocytosis. Cell 84:277, 1996
16. Miyazawa K, Toyama K, Gotoh A, Hendrie PC, Mante C, Broxmeyer HE: Ligand-dependent polyubiquitination of c-kit gene product: a possible mechanism of receptor down modulation in M07e cells. Blood 83:137, 1994
17. Kouro T, Kikuchi Y, Kanazawa H, Hirokawa K, Harada N, Shiiba M, Wakao H, Takaki S, Takatsu K: Critical proline residues of the cytoplasmic domain of the IL-5 receptor alpha chain and its function in IL-5-mediated activation of JAK kinase and STAT5. Int Immunol 8:237, 1996
18. O'Farrell AM, Ichihara M, Mui AL, Miyajima A: Signaling pathways activated in a unique mast cell line where interleukin-3 supports survival and stem cell factor is required for a proliferative response. Blood 87:3655, 1996
19. Leslie KB, Jalbert S, Orban P, Welham M, Duronio V, Schrader JW: Genetic basis of hypo-responsiveness of A/J mice to interleukin-3. Blood 87:3186, 1996
20. Cornelis S, Fache I, Van der Heyden J, Guisez Y, Tavernier J, Devos R, Fiers W, Plaetinck G: Characterization of critical residues in the cytoplasmic domain of the human interleukin-5 receptor alpha chain required for growth signal transduction. Eur J Immunol 25:1857, 1995
21. McCloskey P, Pierce J, Koski RA, Varnum B, Liu ET: Activation of the Axl receptor tyrosine kinase induces mitogenesis and transformation in 32D cells. Cell Growth Differ 5:1105, 1994
22. Silvennoinen O, Witthuhn BA, Quelle FW, Cleveland JL, Yi T, Ihle JN: Structure of the murine Jak2 protein-tyrosine kinase and its role in interleukin 3 signal transduction. Proc Natl Acad Sci USA 90:8429, 1993
23. Yi T, Mui AL-F, Krystal G, Ihle JN: Hematopoietic cell phosphatase associates with the interleukin-3 (IL-3) receptor β chain and down-regulates IL-3-induced tyrosine phosphorylation and mitogenesis. Mol Cell Biol 13:7577, 1993
24. Pan CX, Fukunaga R, Yonehara S, Nagata S: Unidirectional cross-phosphorylation between the granulocyte colony-stimulating factor and interleukin 3 receptors. J Biol Chem 268:25818, 1993
25. Duronio V, Clark-Lewis I, Federsppiel B, Wieler JS, Schrader JW: Tyrosine phosphorylation of receptor beta subunits and common substrates in response to interleukin-3 and granulocyte-macrophage colony stimulating factor. J Biol Chem 267:21856, 1992
26. Schindler C, Darnell JE Jr: Transcriptional responses to polypeptide ligands: The JAK-STAT pathway. Annu Rev Biochem 64:621, 1995
27. Briscoe J, Kohlhuber F, Müller M: JAKs and STATs branch out. TICB 6:336, 1996
28. Chin H, Nakamura N, Kamiyama R, Miyasaka N, Ihle JN, Miura O: Physical and functional interactions between Stat5 and the tyrosine-phosphorylated receptors for erythropoietin and interleukin-3. Blood 88:4415, 1996
29. Gouilleux F, Wakao H, Mundt M, Groner B: Prolactin induces phosphorylation of Tyr694 of STAT5 (MGF), a prerequisite for DNA binding and induction of transcription. EMBO J 13:4361, 1994
30. Ihle JN: STATs: Signal transducers and activators of transcription. Cell 84:331, 1996
31. Azam M, Erdjument-Bromage H, Kreider BL, Xia M, Quelle F, Basu R, Saris C, Tempst P, Ihle JN, Schindler C: Interleukin-3 signals through multiple isoforms of Stat5. EMBO J 14:1402, 1995
32. Mui AL-F, Wakao H, Kinoshita T, Kitamura T, Miyajima A: Suppression of interleukin-3-induced gene expression by a C-terminal truncated Stat5-Role of Stat5 in proliferation. EMBO J 15:2425, 1996
33. Mui AL-F, Wakao H, O'Farrell A-M, Harada N, Miyajima A: Interleukin-3, granulocyte-macrophage colony stimulating factor and interleukin-5 transduce signals through two STAT5 homologs. EMBO J 14:1166, 1995
34. 3 cells: Structural requirements and effect on STAT5 binding. Blood 89:3175, 1997
35. Haspel RL, Salditt-Georgieff M, Darnell JE Jr: The rapid inactivation of nuclear tyrosine phosphorylated Stat1 depends upon a protein tyrosine phosphatase. EMBO J 15:6262, 1996
36. Kim TK, Maniatis T: Regulation of interferon-gamma-activated STAT1 by the ubiquitin-proteasome pathway. Science 273:1717, 1996
37. Piao XH, Paulson R, Vandergeer P, Pawson T, Bernstein A: Oncogenic mutation in the kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase Shp-1. Proc Natl Acad USA 93:14665, 1996
38. Palacios R, Steinmetz M: IL-3-dependent mouse clones that express B-220 antigen, contain Ig genes in germ-line configuration and generate B lymphocytes in vivo. Cell 41:727, 1985
39. Andrews NC, Faller DV: A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucl Acids Res 19:11, 1991
40. Van der Heyden J, Devos R, Plaetinck G, Fache I, Fiers W, Tavernier J: Characterization of the murine IL-5 receptor complex with the use of a panel of monoclonal antibodies. Relationship to the murine IL-3 receptor. J Immunol 147:3413, 1991
41. Barber DL, Beattie BK, D'Andréa DA, Frank DA: An activationspecific STAT5 antibody selectively recognizes the tyrosine phosphorylated forms of the erythropoietin receptor and STAT5. Blood 88:53a, 1996 (abstr, suppl 1)
42. Luo H, Rose P, Barber D, Hanratty WP, Lee S, Roberts TM, D'Andrea AD, Dearolf CR: Mutation in the Jak kinase Jh2 domain hyperactivates Drosophila and mammalian Jak-Stat pathways. Mol Cell Biol 17:1562, 1997
43. Beadling C, Ng J, Babbage JW, Cantrell DA: Interleukin-2 activation of STAT5 requires the convergent action of tyrosine kinases and a serine/threonine kinase pathway distinct from the Raf1/Erk2 MAP kinase pathway. EMBO J 15:1902, 1996
44. Strous GJ, Vankerhof P, Govers R, Rotwein P, Schwartz AL: Growth hormone-induced signal transduction depends on an intact ubiquitin system. J Biol Chem 272:40, 1997
45. He T-C, Jiang N, Zhuang H, Wojchowski DM: Erythropoietininduced recruitment of Shc via a receptor phosphotyrosine-independent, Jak2-associated pathway. J Biol Chem 270:11055, 1995
46. Barber DL, Corless CN, Xia K, Roberts TM, D'Andrea AD: Erythropoietin activates Raf1 by an Shc-independent pathway in Ctll-Epo-R cells. Blood 89:55, 1997
47. Govers R, van Kerkhof P, Schwartz AL, Strous GJ: Linkage of the ubiquitin-conjugating system and the endocytic pathway in ligand-induced internalization of the growth hormone receptor. EMBO J 16:4851, 1997
48. Yu C-L, Burakoff SJ: Involvement of proteasomes in regulating JAK-STAT pathways upon interleukin-2 stimulation. J Biol Chem 272:14017, 1997
49. Wang D, Stravopodis D, Teglund S, Kitazawa J, Ihle JN: Naturally occurring dominant negative variants of Stat5. Mol Cell Biol 16:6141, 1996
50. Moriggl R, Gouilleux-Gruart V, Jahne R, Berchtold S, Gartmann C, Liu X, Hennighausen L, Sotiropoulos A, Groner B, Gouilleux F: Deletion of the carboxyl-terminal transactivation domain of MGF-Stat5 results in sustained DNA binding and a dominant negative phenotype. Mol Cell Biol 16:5691, 1996
51. Jiao H, Berrada K, Yang W, Tabrizi M, Plantanias LC, Yi T: Direct association with and dephosphorylation of JAK2 kinase by the SH2-domain-containing protein tyrosine phosphatase SHP-1. Mol Cell Biol 16:6985, 1996
52. Yin T, Shen R, Feng GS, Yang YC: Molecular characterization of specific interactions between SHP-2 phosphatase and JAK tyrosine kinases. J Biol Chem 272:1032, 1997
53. Maegawa H, Kashiwagi A, Fujita T, Ugi S, Hasegawa M, Obata T, Nishio Y, Kojima H, Hidaka H, Kikkawa R: SHPTP2 serves adapter protein linking between Janus kinase 2 and insulin receptor substrates. Biochem Biophys Res Commun 228:122, 1996
54. Sengupta TK. Schmitt EM, Ivashkiv LB: Inhibition of cytokines and JAK-STAT activation by distinct signaling pathways. Proc Natl Acad Sci USA 93:9499, 1996
55. David M, Chen HE, Goelz S, Lamer AC, Neel BG: Differential regulation of the alpha/beta interferon-stimulated Jak/Stat pathway by the SH2 domain-containing tyrosine phosphatase SHPTP1. Mol Cell Biol 15:7050, 1995
56. Starr R, Willson TA, Viney EM, Murray LJL, Rayner JR, Jenkins BJ, Gonda TJ, Alexander WS, Metcalf D, Nicola NA, Hilton DJ: A family of cytokine-inducible inhibitors of signalling. Nature 387:917, 1997
57. Naka T, Narazaki M, Hirata M, Matsumoto T, Minamoto S, Aono A, Nishimoto N, Kajita T, Taga T, Yoshizaki K, Akira S, Kishimoto T: Structure and function of a new Stat-induced Stat inhibitor. Nature 387:924, 1997
58. Endo TA, Masuhara M, Yokouchi M, Suzuki R, Sakamoto H, Mitsui K, Matsumoto A, Tanimura S, Ohtsubo M, Misawa H, Miyazaki T, Leonor N, Taniguchi T, Fujita T, Kanakura Y, Komiya S, Yoshimura A: A new protein containing an Sh2 domain that inhibits Jak kinases. Nature 387:921, 1997
59. Zhu Y, Carroll M, Papa FR, Hochstrasser M, D'Andrea AD: DUB-1, a deubiquitinating enzyme with growth-suppressing activity. Proc Natl Acad Sci USA 93:3275, 1996